Monitoring of cyclosporin and azathioprine in organ transplantation

Drug Metabolism and Drug Interactions

Volumn 14, Issue 1, 1997, Pages 17-31

  Oellerich, M ^a   Schutz E ^a   Armstrong, V W ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; STEROID; THIOPURINE METHYLTRANSFERASE;

ACCURACY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; RADIOIMMUNOASSAY;

EID: 0031466174     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.1997.14.1.17     Document Type: Conference Paper

References (33)

1. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 1990; 36: 1841-1846.
2. Morris RG, Tett SE, Ray JE. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994; 16: 570-576.
3. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642-654.
4. Evans WE, Homer M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119: 985-989.
5. Schulz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter] [see comments]. Lancet 1993; 341: 436.
6. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [letter; comment]. Lancet 1993, 341: 1151.
7. Frizzera G. Atypical lymphoproliferative disorders. In: Knowles DM, ed. Neoplastic Hematopathology. Baltimore, MD: Willilams and Wilkins, 1992; 459-495.
8. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996; 42: 1316-1321.
9. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-547.
10. Wesselborg S, Fruman DA, Sagoo JK, Bierer BE, Burakoff SJ. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem 1996; 271: 1274-1277.
11. Batiuk TD, Pazderka F, Enns J, De Castro L, Halloran PF. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation 1996; 61: 158-161.
12. Holt DW, Johnston A, Roberts NB, Tredger JM, Trull AK. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994; 31: 420-446.
13. Heller C, Schutz E, Armstrong VW, Oellerich M. Improved EMIT assay for semiautomated cyclosporine determination. Ther Drug Monit 1995; 17: 416.
14. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utililty of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994; 58: 989-996.
15. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-644.
16. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991; 37: 1905-1908.
17. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 1996; 42: 1294-1296.
18. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
19. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511.
20. Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period - predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 1119-1123.
21. Dawidson I, Ar'Rajab A, Lu C, Melone D, Provost D, Wheeler D. Cyclosporine A blood levels predict acute rejections as well as cyclosporine A toxicity after simultaneous pancreas-kidney transplantation. Transplant Proc 1994; 26: 2757-2758.
22. Christians U, Kohlhaw K, Budniak J, et al. Cyclosporin metabolite pattern in blood and urine of liver graft recipients. II. Influence of cholestasis and rejection. Eur J Clin Pharmacol 1991; 41: 291-296.
23. Donatsch P, Rickenbacher U, Ryffel B, Brouillard JF. Sandimmun metabolites: their potential to cause adverse reactions in the rat. Transplant Proc 1990; 22: 1137-1140.
24. Wonigeit K, Kohlhaw K, Winkler M, Schaefer O, Pichlmayr R. Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 1990; 22: 1305-1311.
25. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1990; 32: 651-662.
26. Tinel M, Berson A, Pessayre D, et al. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 1991; 32: 729-734.
27. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 15-20.
28. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92: 949-953.
29. Tai HL, Krynetski EY, Krynetskaia NF, Yates CR, Evans WE. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694-702.
30. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
31. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229.
32. Schütz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996; 34: 199-205.
33. Schütz E, Gummert J, Mohr FM, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18: 228-233.